Skip to main content
Figure 4 | BMC Cancer

Figure 4

From: Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status

Figure 4

Sorafenib suppressed phosphorylation of ERK, p38-MAP kinase, JNK and AKT in SW1736 and BHT101 thyroid carcinoma cells. Cells were treated with 3 μM sorafenib for 1, 5 and 10 minutes. Whole-cell lysates were examined using western blot analysis. Expression of total protein was used as control. Signal intensities of phosphorylated proteins were corrected for signal intensities of total proteins and expressed as percent of untreated control.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us